Long-term persistence of zoster vaccine efficacy.

BACKGROUND: The Shingles Prevention Study (SPS) demonstrated zoster vaccine efficacy through 4 years postvaccination. A Short-Term Persistence Substudy (STPS) demonstrated persistence of vaccine efficacy for at least 5 years. A Long-Term Persistence Substudy (LTPS) was undertaken to further assess vaccine efficacy in SPS vaccine recipients followed for up to 11 years postvaccination. Study outcomes were assessed for the entire LTPS period and for each year from 7 to 11 years postvaccination. METHODS: Surveillance, case determination, and follow-up were comparable to those in SPS and STPS. Because SPS placebo recipients were offered zoster vaccine before the LTPS began, there were no unvaccinated controls. Instead, SPS and STPS placebo results were used to model reference placebo groups. RESULTS: The LTPS enrolled 6867 SPS vaccine recipients. Compared to SPS, estimated vaccine efficacy in LTPS decreased from 61.1% to 37.3% for the herpes zoster (HZ) burden of illness (BOI), from 66.5% to 35.4% for incidence of postherpetic neuralgia, and from 51.3% to 21.1% for incidence of HZ, and declined for all 3 outcome measures from 7 through 11 years postvaccination. Vaccine efficacy for the HZ BOI was significantly greater than zero through year 10 postvaccination, whereas vaccine efficacy for incidence of HZ was significantly greater than zero only through year 8. CONCLUSIONS: Estimates of vaccine efficacy decreased over time in the LTPS population compared with modeled control estimates. Statistically significant vaccine efficacy for HZ BOI persisted into year 10 postvaccination, whereas statistically significant vaccine efficacy for incidence of HZ persisted only through year 8.

Safety of zoster vaccine in elderly adults following documented herpes zoster.

BACKGROUND: After completion of the Shingles Prevention Study (SPS; Department of Veterans Affairs Cooperative Studies Program Number 403), SPS participants who had initially received placebo were offered investigational zoster vaccine without charge. This provided an opportunity to determine the relative safety of zoster vaccine in older adults following documented herpes zoster (HZ). METHODS: A total of 13 681 SPS placebo recipients who elected to receive zoster vaccine were followed for serious adverse events (SAE) for 28 days after vaccination. In contrast to the SPS, a prior episode of HZ was not a contraindication to receiving zoster vaccine. The SPS placebo recipients who received zoster vaccine included 420 who had developed documented HZ during the SPS. RESULTS: The mean interval between the onset of HZ and the receipt of zoster vaccine in the 420 recipients with prior HZ was 3.61 years (median interval, 3.77 years [range, 3-85 months]); the interval was <5 years for approximately 80% of recipients. The proportion of vaccinated SPS placebo recipients with prior HZ who developed ≥ 1 SAE (0.95%) was not significantly different from that of vaccinated SPS placebo recipients with no prior history of HZ (0.66%), and the distribution of SAEs in the 2 groups was comparable. CONCLUSIONS: These results demonstrate that the general safety of zoster vaccine in older persons is not altered by a recent history of documented HZ, supporting the safety aspect of the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recommendation to administer zoster vaccine to all persons ≥ 60 years of age with no contraindications, regardless of a prior history of HZ.

Infectious diseases resources for the iPhone.

Modern technology has revolutionized the clinician's ability to have vast information resources available literally at one's fingertips. The advent of the smartphone--an integration of the mobile phone with an ultraportable computer, web browser, multimedia player, and camera, has given clinicians the capability to merge their information and communication resources into one compact handheld instrument. Apple's iPhone, and its sister device, the iPod touch, with a combined customer base of more than 50 million users and more than 100,000 downloadable applications, are now the leading handheld platforms for medical personnel to access personal information, medical reference, clinical data, and medically oriented "apps" on the go. The purpose of this article is to provide an overview of some of the diverse infectious diseases-oriented resources available to the iPhone/iPod touch user.

Sticks and bones: Traumatic phaeohyphomycosis presenting as an epidural scalp abscess and cranial osteomyelitis.

The pigmented molds can cause soft tissue and invasive disease (phaeohyphomycosis) in immunocompetent patients. We describe a 76-year-old male patient who developed a Cladophialophora bantiatum posterior scalp abscess and cranial osteomyelitis following an incidental scalp exposure with a tree branch. Management requires extensive surgical debridement followed by prolonged antifungal therapy.

Disseminated Acanthamoeba sinusitis in a patient with AIDS: a possible role for early antiretroviral therapy.

Acanthamoeba, a free-living ameba, has been reported to infect humans with subacute encephalitis, sinusitis, or keratitis. Multiple cases of Acanthamoeba sinusitis with dissemination have been reported in association with AIDS, with high mortality. We report successful treatment of a 35-year-old woman who presented with sinusitis that progressed to disseminated acanthamebiasis as her initial manifestation of AIDS. To our knowledge, our patient was one of the few and longest-lived survivors of disseminated Acanthamoeba infection with AIDS. As with other opportunistic infections, early aggressive therapy including HAART may alter the outcome in this almost uniformly fatal disease.

Skin manifestations of herpesvirus infections.

Currently there are eight human herpesviruses identified that cause disease in both adults and children. Although the manifestations of disease differ with each herpesvirus, cutaneous presentations are common among almost all of them. These skin manifestations may be visually similar among several of these viruses, occasionally making it challenging to diagnose the patient's illness. Laboratory diagnostic testing is commercially available for most of these viruses. Because many herpesvirus infections are self-limiting in immunocompetent hosts, patients require only supportive care. Effective antiviral therapy is available for the more severe cases of infection caused by herpes simplex virus (HSV), varicella zoster virus (VZV), or cytomegalovirus (CMV). Healthcare practitioners should become familiar with the different cutaneous manifestations these viruses may exhibit.